FDA approves schizophrenia drug that could alter how disorder is treated
For decades, doctors caring for people with schizophrenia have relied on mood-regulating drugs that target the brain chemical dopamine. On Thursday, the Food and Drug
For decades, doctors caring for people with schizophrenia have relied on mood-regulating drugs that target the brain chemical dopamine. On Thursday, the Food and Drug
This story first appeared in Adam’s Biotech Scorecard, a subscriber-only newsletter. STAT+ subscribers can sign up here to get it delivered to their inbox. I love a
This story first appeared in Adam’s Biotech Scorecard, a subscriber-only newsletter. STAT+ subscribers can sign up here to get it delivered to their inbox. The deep financial restructuring announced
Biogen and UCB said Tuesday that an experimental drug reduced disease activity and symptoms of systemic lupus, achieving the primary goal of a placebo-controlled Phase
Senior Writer, Biotech Adam Feuerstein is a senior writer and biotech columnist, reporting on the crossroads of drug development, business, Wall Street, and biotechnology. He
Senior Writer, Biotech Adam Feuerstein is a senior writer and biotech columnist, reporting on the crossroads of drug development, business, Wall Street, and biotechnology. He
Viridian Therapeutics said Tuesday that an experimental treatment improved the signs and symptoms of thyroid eye disease — results that achieved the primary goals of
For months, investors have been asking Roivant Sciences chief executive Matt Gline to reveal the next drug it planned to buy with some of the
With strong data released over the weekend, an experimental Chinese drug showed it could one day become an important therapy for lung cancer patients. But
A CRISPR-augmented stem cell transplant that protects healthy cells from the toxic effects of anti-cancer medicines has shown preliminary evidence that it can delay relapse